Many UK digital health companies still see France as a difficult market to approach.

Many UK digital health companies still see France as a difficult market to approach.
-Too complex.
-Too regulated.
-Too different from the NHS environment.

But from what I observe in digital health and chronic disease management, the challenge is often misunderstood.
Entering the French healthcare market is rarely just a regulatory or compliance issue. It is a question of clinical communication, medical trust, and adaptation to local healthcare systems.

A solution that performs very well within the NHS may still struggle in France if:
- The clinical value proposition does not resonate with French healthcare professionals and specialists.
- The patient communication feels too foreign or disconnected from French care pathways.
- The solution has not been adapted to local clinical workflows and healthcare expectations.

This is particularly evident in high-stakes fields such as:
- Diabetes care and metabolic health
- Chronic disease management
- Remote patient monitoring
- Digital Therapeutics 

France has significantly accelerated its digital health transformation in recent years through initiatives such as PECAN, the Ségur du Numérique en Santé, and the France 2030 investment plan. The ecosystem is evolving quickly, and there is genuine interest for well-designed digital health solutions.

But successful adoption often depends on something far more subtle than regulatory compliance: understanding how credibility and trust are built within the French medical community.

Healthcare localization is not simply about translating words.
It is about making a solution understandable, credible, and clinically relevant within another healthcare culture.
#digitalhealth #healthtechuk #pecan #chroniccare #healthcarelocalization